Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire May 1, 2018

Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline

GlobeNewswire April 16, 2018

Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401

GlobeNewswire April 5, 2018

Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire March 19, 2018

Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference

GlobeNewswire March 19, 2018

Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results

GlobeNewswire March 16, 2018

Stemline Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire March 8, 2018

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

GlobeNewswire January 26, 2018

Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock

GlobeNewswire January 24, 2018

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire January 22, 2018

Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML

Business Wire January 8, 2018

Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2018

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

GlobeNewswire December 13, 2017

Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting

GlobeNewswire December 8, 2017

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

GlobeNewswire November 16, 2017

Stemline Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 9, 2017

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting

GlobeNewswire November 1, 2017

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint

GlobeNewswire October 31, 2017

Stemline Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 20, 2017

Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

GlobeNewswire September 11, 2017